Objective:To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma.Methods:60 cases of multiple myeloma patients admitted to our hospital from January 2022 ...Objective:To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma.Methods:60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly,with 30 cases in each group.Bortezomib combined with dexamethasone was administered in the control group,and bortezomib combined with dexamethasone and lenalidomide was given to the observation group,and the treatment effect was analyzed.Results:After treatment,CD^(3+)and CD^(4+)of the observation group were higher than that of the control group,CD^(8+)was lower than that of the control group,and the total treatment efficiency was higher,which was statistically significant(P<0.05),and there was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe,thus it can be promoted in clinical practice.展开更多
Objective:Metabolic disorders are regarded as hallmarks of multiple myeloma(MM)and are responsible for rapid cancer cell proliferation and tumor growth.However,the exact biological roles of metabolites in MM cells hav...Objective:Metabolic disorders are regarded as hallmarks of multiple myeloma(MM)and are responsible for rapid cancer cell proliferation and tumor growth.However,the exact biological roles of metabolites in MM cells have not been fully explored.This study aimed to explore the feasibility and clinical significance of lactate for MM and investigate the molecular mechanism of lactic acid(Lac)in the proliferation of myeloma cells and cell sensitivity to bortezomib(BTZ).Methods:Metabolomic analysis of the serum was carried out to obtain metabolites expression and clinical characteristics in MM patients.The CCK8 assay and flow cytometry were used to detect cell proliferation,apoptosis,and cell cycle changes.Western blotting was used to detect the potential mechanism and apoptosis-and cycle-related protein changes.Results:Lactate was highly expressed in both the peripheral blood and bone marrow of MM patients.It was significantly correlated with Durie-Salmon Staging(DS Staging)and the International Staging System(ISS Staging)and the serum and urinary involved/uninvolved free light chain ratios.Patients with relatively high lactate levels had a poor treatment response.Moreover,in vitro experiments showed that Lac could promote the proliferation of tumor cells and decrease the proportion of G0/G1-phase cells,which was accompanied by an increased proportion of S-phase cells.In addition,Lac could decrease tumor sensitivity to BTZ by disrupting the expression of nuclear factor kappa B subunit 2(NFκB2)and Re1B.Conclusion:Metabolic changes are important in MM cell proliferation and treatment response;lactate could be used as a biomarker in MM and as a therapeutic target to overcome cell resistance to BTZ.展开更多
Bortezomib, a proteasome inhibitor, is an established therapy against plasma cell leukemia—a variant of plasma cell dyscrasias. Its most frequent side effects have been listed as peripheral neuropathy, neuropathic pa...Bortezomib, a proteasome inhibitor, is an established therapy against plasma cell leukemia—a variant of plasma cell dyscrasias. Its most frequent side effects have been listed as peripheral neuropathy, neuropathic pain, thrombocytopenia, and gastrointestinal problems. Allergic skin reaction is a rarely documented side effect in patients receiving bortezomib-based chemotherapy. A combination therapy consisting of intravenous bortezomib, oral Revlimid tablets, and oral dexamethasone tablets has been prescribed for the patient after his recent diagnosis of plasma cell leukemia. While receiving his third treatment cycle, he developed an allergic reaction (skin rash) involving the neck, and wrists, and mild bilateral eye swelling. The infusion was stopped immediately and then ciprofloxacin ophthalmic solution and oral diphenhydramine 25 mg were prescribed to the patient with significant improvement in his clinical condition. He was temporarily taken off bortezomib. At a follow-up visit a week later, a significant improvement was noticed in his condition. Rash had reduced on neck and wrists, and eye swelling had reduced as well. As of the time of writing this case report, he has been temporarily taken off bortezomib, but other medications in the treatment regimen were continued as prescribed.展开更多
目的:探讨蛋白酶体抑制剂(PI)相关血栓性微血管病(TMA)的发生规律和临床特点,为临床安全用药提供参考。方法:检索中国知网、万方数据库、维普数据库、PubMed、Web of Science等数据库中收录的PI相关TMA的案例报道,检索时间为建库至2023...目的:探讨蛋白酶体抑制剂(PI)相关血栓性微血管病(TMA)的发生规律和临床特点,为临床安全用药提供参考。方法:检索中国知网、万方数据库、维普数据库、PubMed、Web of Science等数据库中收录的PI相关TMA的案例报道,检索时间为建库至2023年4月30日。对患者基本信息、用药情况、TMA的临床表现、实验室检查、治疗及预后进行汇总分析。结果:纳入文献37篇,涉及患者92例,其中男性46例(占50.00%),女性29例(占31.52%),性别不详17例(占18.48%);平均年龄为(61±13)岁。TMA的中位发病时间为64 d,临床表现以发热、乏力、恶心/呕吐、少尿/无尿为主。因1例患者出现2次TMA,则合计93例次TMA,患者血小板计数明显降低,中位值为19.5×10^(9)/L,其中0~50×10^(9)/L的患者最多(52例次,占55.91%);64例次患者(占68.82%)的血清肌酐水平升高,其中>177~445μmol/L的患者最多(32例次,占34.41%)。停药和支持治疗后(共93例次),76例次患者(占81.72%)痊愈/好转,6例次(占6.45%)有后遗症,5例次(占5.38%)死亡。PI相关TMA中,主要涉及的药物为卡非佐米(67例次,占72.04%)。结论:应重视PI所致TMA,应用PI时应考虑患者性别、药物种类等因素;根据临床表现及实验室检查结果,尽早识别不良反应,保障患者用药安全。展开更多
目的:探讨烟酰胺磷酸核糖转移酶(NAMPT)在多发性骨髓瘤中的作用机制及其临床价值。方法:采用RT-q PCR和Western blot方法检测多发性骨髓瘤细胞和正常骨髓单个核细胞中NAMPT的表达水平,同时通过细胞增殖与凋亡实验、小干扰RNA沉默、过表...目的:探讨烟酰胺磷酸核糖转移酶(NAMPT)在多发性骨髓瘤中的作用机制及其临床价值。方法:采用RT-q PCR和Western blot方法检测多发性骨髓瘤细胞和正常骨髓单个核细胞中NAMPT的表达水平,同时通过细胞增殖与凋亡实验、小干扰RNA沉默、过表达实验和染色质免疫共沉淀实验分析NAMPT的生物学功能。结果:多发性骨髓瘤细胞系(MM1R、MM1S、U266和RPMI-8226)中NAMPT m RNA和蛋白的表达水平较正常骨髓单个核细胞均显著升高(P<0.001),且在U266细胞中最明显。与Si-NC组相比,Si-NAMPT组转染24、48、72 h均显著抑制U266细胞增殖(P=0.006,P<0.001,P=0.001),转染48 h时U266细胞凋亡率升高显著(P<0.001)。与Flag-NC组比较,Flag-NAMPT组U266细胞增殖均显著升高(P=0.003,P=0.002,P<0.001),转染48 h时细胞凋亡率明显降低。在U266细胞中NAMPT的表达在转录水平受到XBP1的调控。用硼替佐米处理XBP1或NAMPT稳定敲除或经MKC3946预处理的U266细胞后细胞增殖率均显著下降,BAX m RNA和蛋白水平显著升高,BCL-2 m RNA和蛋白水平显著下调,Caspase-3裂解度显著下降,Caspase-3/7活性急剧增加(P<0.05)。结论:NAMPT在多发性骨髓瘤细胞系中高表达,促进多发性骨髓瘤细胞增殖,抑制细胞凋亡。在U266细胞中NAMPT受IRE1α-XBP1信号通路的转录调控。稳定敲除NAMPT或阻断IRE1α-XBP1通路可显著提高U266细胞对硼替佐米的敏感性。展开更多
基金Shandong Medical Association Clinical Research Specialization(YXH2022ZX03231)。
文摘Objective:To analyze the effect of bortezomib combined with dexamethasone and lenalidomide in the treatment of multiple myeloma.Methods:60 cases of multiple myeloma patients admitted to our hospital from January 2022 to December 2023 were selected randomly,with 30 cases in each group.Bortezomib combined with dexamethasone was administered in the control group,and bortezomib combined with dexamethasone and lenalidomide was given to the observation group,and the treatment effect was analyzed.Results:After treatment,CD^(3+)and CD^(4+)of the observation group were higher than that of the control group,CD^(8+)was lower than that of the control group,and the total treatment efficiency was higher,which was statistically significant(P<0.05),and there was no difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Bortezomib combined with dexamethasone and lenalidomide is effective in the treatment of multiple myeloma as it regulates the immune function and is safe,thus it can be promoted in clinical practice.
基金supported by grants from the National Natural Science Foundation of China(No.82070208)the Military Clinical Medical Innovation Project of Xinqiao Hospital(No.2021JSLC0003)+2 种基金the National Natural Science Foundation of Chongqing(No.cstc2020jcyjmsxmX0433)the Translational Research Grant of NCRCH(Nos.2020ZKZC02,2021WWB05)the Chongqing Science and Health Joint Medical Research Project(Nos.2021MSXM226,2023QNXM047).
文摘Objective:Metabolic disorders are regarded as hallmarks of multiple myeloma(MM)and are responsible for rapid cancer cell proliferation and tumor growth.However,the exact biological roles of metabolites in MM cells have not been fully explored.This study aimed to explore the feasibility and clinical significance of lactate for MM and investigate the molecular mechanism of lactic acid(Lac)in the proliferation of myeloma cells and cell sensitivity to bortezomib(BTZ).Methods:Metabolomic analysis of the serum was carried out to obtain metabolites expression and clinical characteristics in MM patients.The CCK8 assay and flow cytometry were used to detect cell proliferation,apoptosis,and cell cycle changes.Western blotting was used to detect the potential mechanism and apoptosis-and cycle-related protein changes.Results:Lactate was highly expressed in both the peripheral blood and bone marrow of MM patients.It was significantly correlated with Durie-Salmon Staging(DS Staging)and the International Staging System(ISS Staging)and the serum and urinary involved/uninvolved free light chain ratios.Patients with relatively high lactate levels had a poor treatment response.Moreover,in vitro experiments showed that Lac could promote the proliferation of tumor cells and decrease the proportion of G0/G1-phase cells,which was accompanied by an increased proportion of S-phase cells.In addition,Lac could decrease tumor sensitivity to BTZ by disrupting the expression of nuclear factor kappa B subunit 2(NFκB2)and Re1B.Conclusion:Metabolic changes are important in MM cell proliferation and treatment response;lactate could be used as a biomarker in MM and as a therapeutic target to overcome cell resistance to BTZ.
文摘Bortezomib, a proteasome inhibitor, is an established therapy against plasma cell leukemia—a variant of plasma cell dyscrasias. Its most frequent side effects have been listed as peripheral neuropathy, neuropathic pain, thrombocytopenia, and gastrointestinal problems. Allergic skin reaction is a rarely documented side effect in patients receiving bortezomib-based chemotherapy. A combination therapy consisting of intravenous bortezomib, oral Revlimid tablets, and oral dexamethasone tablets has been prescribed for the patient after his recent diagnosis of plasma cell leukemia. While receiving his third treatment cycle, he developed an allergic reaction (skin rash) involving the neck, and wrists, and mild bilateral eye swelling. The infusion was stopped immediately and then ciprofloxacin ophthalmic solution and oral diphenhydramine 25 mg were prescribed to the patient with significant improvement in his clinical condition. He was temporarily taken off bortezomib. At a follow-up visit a week later, a significant improvement was noticed in his condition. Rash had reduced on neck and wrists, and eye swelling had reduced as well. As of the time of writing this case report, he has been temporarily taken off bortezomib, but other medications in the treatment regimen were continued as prescribed.
文摘目的:探讨蛋白酶体抑制剂(PI)相关血栓性微血管病(TMA)的发生规律和临床特点,为临床安全用药提供参考。方法:检索中国知网、万方数据库、维普数据库、PubMed、Web of Science等数据库中收录的PI相关TMA的案例报道,检索时间为建库至2023年4月30日。对患者基本信息、用药情况、TMA的临床表现、实验室检查、治疗及预后进行汇总分析。结果:纳入文献37篇,涉及患者92例,其中男性46例(占50.00%),女性29例(占31.52%),性别不详17例(占18.48%);平均年龄为(61±13)岁。TMA的中位发病时间为64 d,临床表现以发热、乏力、恶心/呕吐、少尿/无尿为主。因1例患者出现2次TMA,则合计93例次TMA,患者血小板计数明显降低,中位值为19.5×10^(9)/L,其中0~50×10^(9)/L的患者最多(52例次,占55.91%);64例次患者(占68.82%)的血清肌酐水平升高,其中>177~445μmol/L的患者最多(32例次,占34.41%)。停药和支持治疗后(共93例次),76例次患者(占81.72%)痊愈/好转,6例次(占6.45%)有后遗症,5例次(占5.38%)死亡。PI相关TMA中,主要涉及的药物为卡非佐米(67例次,占72.04%)。结论:应重视PI所致TMA,应用PI时应考虑患者性别、药物种类等因素;根据临床表现及实验室检查结果,尽早识别不良反应,保障患者用药安全。
文摘目的:探讨烟酰胺磷酸核糖转移酶(NAMPT)在多发性骨髓瘤中的作用机制及其临床价值。方法:采用RT-q PCR和Western blot方法检测多发性骨髓瘤细胞和正常骨髓单个核细胞中NAMPT的表达水平,同时通过细胞增殖与凋亡实验、小干扰RNA沉默、过表达实验和染色质免疫共沉淀实验分析NAMPT的生物学功能。结果:多发性骨髓瘤细胞系(MM1R、MM1S、U266和RPMI-8226)中NAMPT m RNA和蛋白的表达水平较正常骨髓单个核细胞均显著升高(P<0.001),且在U266细胞中最明显。与Si-NC组相比,Si-NAMPT组转染24、48、72 h均显著抑制U266细胞增殖(P=0.006,P<0.001,P=0.001),转染48 h时U266细胞凋亡率升高显著(P<0.001)。与Flag-NC组比较,Flag-NAMPT组U266细胞增殖均显著升高(P=0.003,P=0.002,P<0.001),转染48 h时细胞凋亡率明显降低。在U266细胞中NAMPT的表达在转录水平受到XBP1的调控。用硼替佐米处理XBP1或NAMPT稳定敲除或经MKC3946预处理的U266细胞后细胞增殖率均显著下降,BAX m RNA和蛋白水平显著升高,BCL-2 m RNA和蛋白水平显著下调,Caspase-3裂解度显著下降,Caspase-3/7活性急剧增加(P<0.05)。结论:NAMPT在多发性骨髓瘤细胞系中高表达,促进多发性骨髓瘤细胞增殖,抑制细胞凋亡。在U266细胞中NAMPT受IRE1α-XBP1信号通路的转录调控。稳定敲除NAMPT或阻断IRE1α-XBP1通路可显著提高U266细胞对硼替佐米的敏感性。